RCLIN Group finalizes the 2020 strategy in Davos
Leaders of RCLIN’s pharma and medical businesses came to Davos on the occasion of the 50th anniversary of the World Economic Forum to discuss RCLIN’s 2020 strategy. Supported by the strong outcomes of the R&D efforts, it is planned that no less than 15 new proprietary formulas of food and beauty products will enter production this year. The launch of DR PRUSS™ line of health and beauty products is scheduled in April.
In the meantime, RCLIN clinics for molecular medicine will start offering updated personalized health programs to be supported by individually produced, patient specific formulas at RCLIN’s compounding facilities in Malta. Clients will be offered personalized formulations based on the results of their molecular tests and recommendations of RCLIN’s medical team.
A new business line “RCLIN Health Hospitality” will be launched later this year focusing on wellness retreats to offer clients unique experiences of health vacations.